1207438-38-7

Basic information

• Product Name: tert-butyl 4-[(3-chlorophenyl)(cyano)methylidene]piperidine-1-carboxylate
• Synonyms: tert-butyl 4-[(3-chlorophenyl)(cyano)methylidene]piperidine-1-carboxylate
• CAS NO: 1207438-38-7
• Molecular Weight: 332.83
• Mol File: 1207438-38-7.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: tert-butyl 4-[(3-chlorophenyl)(cyano)methylidene]piperidine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 4-[(3-chlorophenyl)(cyano)methylidene]piperidine-1-carboxylate(1207438-38-7)
• EPA Substance Registry System: tert-butyl 4-[(3-chlorophenyl)(cyano)methylidene]piperidine-1-carboxylate(1207438-38-7)

Safety Data

• Hazardous Substances Data: 1207438-38-7(Hazardous Substances Data)

Upstream product

• 1529-41-5 3-chloro-benzeneacetonitrile 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 

Downstream Products

• 1207436-34-7 4-[(1RS)-1-(3-chlorophenyl)-2-methoxyethyl]piperidine monohydrochloride 
• 1207438-88-7 tert-butyl 4-[(1RS)-1-(3-chlorophenyl)-2-methoxyethyl]piperidine-1-carboxylate 
• 1207438-77-4 tert-butyl 4-[(1RS)-1-(3-chlorophenyl)-2-hydroxyethyl]piperidine-1-carboxylate 
• 1207438-55-8 (2RS)-2-[1-(tert-butoxycarbonyl)piperidin-4-yl]-2-(3-chlorophenyl)ethanoic acid 
• 1207438-57-0 C₁₃H₁₆ClNO₂*BrH 
• 1207438-45-6 tert-butyl 4-[(RS)-(3-chlorophenyl)(cyano)methyl]piperidine-1-carboxylate 

Relevant articles and documents

Novel triple reuptake inhibitors with low risk of CAD associated liabilities: Design, synthesis and biological activities of 4-[(1S)-1-(3,4- dichlorophenyl)-2-methoxyethyl]piperidine and related compounds

A novel triple reuptake inhibitor with low potential of liabilities associated with cationic amphiphilic drug (CAD) was identified following an analysis of existing drugs. Low molecular weight (MW a series of piperidine compounds was designed with consideration of the common characteristic features of CNS drugs. Optimization of the side chain by adjusting overall lipophilicity suggested that incorporation of a methoxymethyl group could provide compounds with a balance of both potent reuptake inhibition and low liability potential. Compound (S)-3a showed a potent antidepressant-like effect in the mice tail suspension test (MED = 10 mg/kg, p.o.), proportional monoamine transporter occupancies and enhancement of monoamine concentrations in mouse prefrontal cortex.